EROTON®

  • Composition
  • Release form
  • Indication
  • Reception scheme
  • Contraindications
Active ingredient: sildenafil; 1 tablet contains sildenafil citrate at doses equivalent to 50 mg or 100 mg of sildenafil. Excipients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, co-povidone, colloidal anhydrous silica, talc, magnesium stearate, sodium crosscarmellose, starch potato.
Tablets 50 mg, 100 mg number 1 (1x1), number 2 (2x1), number 4 (4x1) in a blister pack in.
The drug product is recommended to use men with erectile dysfunction, which is defined as the inability to achieve or maintain penile erection necessary for successful sexual intercourse. For effective action of the drug product required sexual stimulation.
The drug product is used orally. For adults. The recommended dose is 50  mg used if needed about 1 hour before sexual activity. Depending on the efficacy and tolerability the dose may be increased to 100   mg or decreased to 25   mg. The maximum recommended dose is 100   mg. The frequency of application of the maximum recommended dose is 1 time per day. Using the drug product during meal preparation action may occur later than when used on an empty stomach. Elderly patients: the need for dose adjustment in elderly patients (≥ 65 years). Not for children. The drug product is not indicated for use for people under 18 years.
Hypersensitivity to sildenafil or any of the excipients of the drug; simultaneous use with nitric oxide donors (such as amyl nitrite) or nitrates in any form - sildenafil affects the pathways of nitric oxide / cyclic guanosine monophosphate (cGMP) metabolism and potentiates the hypotensive effect of nitrates; the simultaneous use of PDE-5 inhibitors (including sildenafil) with guanylate cyclase stimulants such as riociguat is contraindicated because it can lead to symptomatic hypotension (see Section "Interaction with other medicinal products and other types of interactions"); conditions in which sexual activity is undesirable (severe cardiovascular disorders such as unstable angina or severe heart failure); the drug is contraindicated in patients who have lost vision in one eye due to non-arterial anterior ischemic neuropathy of the optic nerve, regardless of whether this pathology is associated with previous use of PDE-5 inhibitors or not; the presence of diseases such as severe liver dysfunction, arterial hypotension (blood pressure below 90/50 mm Hg), recent stroke or myocardial infarction, and hereditary degenerative retinal diseases such as retinitis pigmentosa (such patients may have genetic disorders Retinal PDE) - the safety of sildenafil has not been investigated in these patient subgroups.
Price information